HRMY Growth Trends Beyond Wakix Could Shape Its Next Growth Phase

Harmony Biosciences Holdings, Inc. HRMY is no longer only a Wakix revenue story. The company is using its sleep-wake franchise to fund a broader neuroscience strategy.The central question is whether those emerging growth trends can turn pipeline investment into a more diversified business before co…

Harmony Biosciences Holdings, Inc. HRMY is no longer only a Wakix revenue story. The company is using its sleep-wake franchise to fund a broader neuroscience strategy.

The central question is whether those emerging growth trends can turn pipeline investment into a more diversified business before competition and exclusivity risks pressure the core product.

Harmony Pushes Beyond One Indication

Harmony is working to extend pitolisant beyond its established narcolepsy base. Its late-stage clinical work includes idiopathic hypersomnia, Prader-Willi syndrome and myotonic dystrophy type 1.

That approach reflects a broader attempt to extract more value from an established mechanism across adjacent neurological settings. Rather than relying only on new patient starts in narcolepsy, HRMY is trying to build a wider clinical footprint around the same scientific foundation.

Why HRMY Is Chasing Better Formulations

Pitolisant Gastro-Resistant and Pitolisant High-Dose are central to that lifecycle strategy. The gastro-resistant version is intended to allow patients to start at a therapeutic dose without titration, while potentially improving tolerability for patients prone to gastrointestinal symptoms.

The high-dose version targets a more differentiated label. Ongoing Phase III programs in narcolepsy and idiopathic hypersomnia are aimed at fatigue in narcolepsy and sleep inertia in idiopathic hypersomnia, with top-line data expected in 2027 and a target action date in 2028. For HRMY, formulation work is not just incremental. It is a way to defend the franchise and sharpen commercial positioning.

How Harmony Is Entering Orexin and Rare Epilepsy

Harmony’s BP1.15205 program moves the company into orexin-2 receptor agonism, an emerging area in sleep-wake therapeutics. The candidate is being developed for narcolepsy and other potential indications, and Harmony has described BP-205 as a highly potent, selective orexin-2 receptor agonist with potential once-daily dosing.

The company is also moving deeper into rare epilepsy through EPX-100, or clemizole hydrochloride. EPX-100 is enrolling in two global Phase III registrational trials in Lennox-Gastaut syndrome and Dravet syndrome. Jazz Pharmaceuticals plc JAZZ, which has exposure to rare sleep disorders and rare epilepsies, offers a useful comparison for how sleep and epilepsy franchises can sit within one neuroscience business.

Alkermes plc ALKS, another neuroscience-focused peer, also highlights investor interest in central nervous system portfolios beyond single-product stories.

Harmony Biosciences Holdings, Inc. Price, Consensus and EPS Surprise

Harmony Biosciences Holdings, Inc. price-consensus-eps-surprise-chart | Harmony Biosciences Holdings, Inc. Quote

What Competition Means for HRMY’s Future

More treatment development in narcolepsy and related disorders can help validate demand. A more active category may increase physician awareness, expand payer familiarity and reinforce the need for differentiated therapies.

The same trend also raises pressure. Multiple orexin-2 receptor agonists are moving toward approval or late-stage development, while Harmony’s BP-205 remains early. More choices could narrow the window for differentiation, increase payer scrutiny and make execution around access, positioning and persistence more important.

How Harmony’s Ratings Reflect These Trends

The bottom line is that Harmony has credible growth trends, but the stock still needs proof that they can translate into broader revenue durability. Wakix remains the commercial engine, while pitolisant lifecycle programs, orexin science and rare epilepsy assets represent the next phase of the story.

HRMY carries a Zacks Rank #3 (Hold), which points to a more balanced short-term setup rather than a clear momentum call. Its Value Score of A and VGM Score of A suggest the stock screens well on valuation and combined style characteristics, while its Growth Score of B supports the view that fundamental expansion remains part of the case.

The Momentum Score of D tempers that message. Investors may need patience as the market waits for clearer evidence from Pitolisant GR, Pitolisant HD, BP-205 and EPX-100. The signals line up with a company investing into promising trends, but not yet with a stock that has fully earned a breakout narrative.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report